Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVDL Avadel Pharmaceuticals	$10.65 +2.6%	$9.36	$6.38 ▼ $17.30	$1.00B	1.42	1.23 million shs	1.64 million shs
AVXL Anavex Life Sciences	$11.26 +3.6%	$8.88	$4.93 ▼ $14.44	$928.48M	0.72	1.19 million shs	1.17 million shs
ESPR Esperion Therapeutics	$1.12 -0.9%	$1.02	$0.69 ▼ $3.94	$223.96M	0.7	4.70 million shs	2.20 million shs
RCUS Arcus Biosciences	$9.26 +2.6%	$8.93	$6.50 ▼ $18.98	$956.14M	0.8	885,670 shs	494,341 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVDL Avadel Pharmaceuticals	+2.60%	+11.52%	+12.11%	+32.63%	-37.02%
AVXL Anavex Life Sciences	+3.59%	+4.65%	+30.78%	+25.81%	+93.14%
ESPR Esperion Therapeutics	-0.88%	-8.94%	-4.27%	+17.89%	-58.97%
RCUS Arcus Biosciences	+2.56%	-0.53%	+1.97%	+17.45%	-41.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVDL Avadel Pharmaceuticals	1.8551 of 5 stars	3.5	1.0	0.0	1.6	1.7	0.6
AVXL Anavex Life Sciences	3.9885 of 5 stars	3.7	1.0	4.7	3.1	0.8	0.6
ESPR Esperion Therapeutics	3.9398 of 5 stars	3.4	2.0	3.9	2.5	1.7	0.6
RCUS Arcus Biosciences	2.3103 of 5 stars	4.4	1.0	0.0	1.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVDL Avadel Pharmaceuticals	3.00	Buy	$18.17	70.58% Upside
AVXL Anavex Life Sciences	3.33	Buy	$44.00	290.76% Upside
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	525.00% Upside
RCUS Arcus Biosciences	2.89	Moderate Buy	$21.29	129.84% Upside

Current Analyst Ratings Breakdown

Latest ESPR, RCUS, AVDL, and AVXL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/9/2025	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $22.00
5/8/2025	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
5/8/2025	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
5/7/2025	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00
5/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $26.00
4/25/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/25/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/23/2025	RCUS Arcus Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $14.00
4/17/2025	ESPR Esperion Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $3.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVDL Avadel Pharmaceuticals	$169.12M	6.09	N/A	N/A	$0.77 per share	13.83
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.42 per share	N/A
ESPR Esperion Therapeutics	$332.31M	0.67	$0.02 per share	47.03	($1.97) per share	-0.57
RCUS Arcus Biosciences	$258M	3.80	N/A	N/A	$5.30 per share	1.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVDL Avadel Pharmaceuticals	-$48.83M	-$0.27	N/A	177.50	N/A	-13.58%	-36.07%	-16.30%	8/6/2025 (Estimated)
AVXL Anavex Life Sciences	-$43M	-$0.55	N/A	N/A	N/A	N/A	-40.93%	-36.38%	8/5/2025 (Estimated)
ESPR Esperion Therapeutics	-$51.74M	-$0.80	N/A	N/A	N/A	-59.03%	-0.91%	-29.47%	8/11/2025 (Estimated)
RCUS Arcus Biosciences	-$283M	-$4.19	N/A	N/A	N/A	-258.94%	-70.58%	-32.97%	8/4/2025 (Estimated)

Latest ESPR, RCUS, AVDL, and AVXL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	ESPR Esperion Therapeutics	-$0.17	N/A	N/A	N/A	$62.55 million	N/A
8/5/2025	Q3 2025	AVXL Anavex Life Sciences	-$0.13	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q2 2025	AVXL Anavex Life Sciences	-$0.16	-$0.13	+$0.03	-$0.13	N/A	N/A
5/7/2025	Q1 2025	AVDL Avadel Pharmaceuticals	-$0.07	-$0.05	+$0.02	-$0.05	$50.57 million	$52.51 million
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million
5/6/2025	Q1 2025	RCUS Arcus Biosciences	-$1.02	-$1.14	-$0.12	-$1.14	$38.61 million	$28.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVDL Avadel Pharmaceuticals	N/A	2.73	2.33
AVXL Anavex Life Sciences	N/A	6.74	6.74
ESPR Esperion Therapeutics	N/A	1.18	0.81
RCUS Arcus Biosciences	0.09	5.37	5.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVDL Avadel Pharmaceuticals	69.19%
AVXL Anavex Life Sciences	31.55%
ESPR Esperion Therapeutics	47.39%
RCUS Arcus Biosciences	92.89%

Insider Ownership

Company	Insider Ownership
AVDL Avadel Pharmaceuticals	5.20%
AVXL Anavex Life Sciences	11.40%
ESPR Esperion Therapeutics	1.70%
RCUS Arcus Biosciences	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVDL Avadel Pharmaceuticals	70	96.74 million	91.71 million	Optionable
AVXL Anavex Life Sciences	40	85.42 million	75.64 million	Optionable
ESPR Esperion Therapeutics	200	198.20 million	194.83 million	Optionable
RCUS Arcus Biosciences	500	105.89 million	95.72 million	Optionable

ESPR, RCUS, AVDL, and AVXL Headlines

Recent News About These Companies

Arcus Biosciences (NYSE:RCUS) Shares Down 4.6% - Here's What Happened

July 15 at 2:44 PM | marketbeat.com

Arcus Biosciences’ quemliclustat receives US FDA orphan drug designation to treat pancreatic cancer

July 15 at 10:59 AM | pharmabiz.comP

Arcus Biosciences' Quemliclustat Gets Orphan Drug Status For ... - Nasdaq

July 12, 2025 | nasdaq.com

Arcus Biosciences’ cancer drug gets orphan drug status

July 11, 2025 | msn.com

Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances

July 11, 2025 | appliedclinicaltrialsonline.comA

Arcus’ Quemliclustat Receives Orphan Drug Designation

July 11, 2025 | contractpharma.comC

Arcus Biosciences' Pancreatic Cancer Treatment Gets Orphan Drug Status

July 11, 2025 | marketwatch.com

Arcus Biosciences’ Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer

July 11, 2025 | finance.yahoo.com

Arcus Biosciences (NYSE:RCUS) Shares Gap Up - Here's Why

July 10, 2025 | marketbeat.com

Arcus Biosciences' Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer

July 10, 2025 | gurufocus.com

Arcus Biosciences (NYSE:RCUS) Stock Price Up 8.1% - Should You Buy?

July 9, 2025 | marketbeat.com

Arcus Biosciences Announces New Employment Inducement Grants

July 9, 2025 | businesswire.com

Arcus Biosciences (NYSE:RCUS) Trading Down 2.9% - Here's What Happened

July 3, 2025 | marketbeat.com

Arcus Biosciences Presents First Postive Data for Oral Metastatic Kidney Cancer Treatment

July 1, 2025 | msn.com

Arcus Biosciences (NYSE:RCUS) Trading Down 6.3% - Here's What Happened

June 27, 2025 | marketbeat.com

Incyte, FDA, Sun Pharma and more—Chutes & Ladders

June 27, 2025 | fiercebiotech.comF

Arcus Biosciences Announces New Employment Inducement Grants - Business Wire

June 26, 2025 | businesswire.com

Precision Bio's DMD Therapy Gets Rare Pediatric Status, But Stock Slides; Retail Crowd Sees ‘Good Risk-Reward’

June 26, 2025 | msn.com

Precision BioSciences Shares Surge Following FDA Rare Pediatric Disease Designation

June 25, 2025 | msn.com

Precision BioSciences gets FDA rare disease status for DMD treatment, stock jumps 10%

June 25, 2025 | msn.com

Arcus Biosciences, Inc. (RCUS) Cash Flow - Yahoo Finance

June 24, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESPR, RCUS, AVDL, and AVXL Company Descriptions

Avadel Pharmaceuticals NASDAQ:AVDL

$10.65 +0.27 (+2.60%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$10.64 -0.01 (-0.05%)

As of 07/16/2025 04:48 PM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Anavex Life Sciences NASDAQ:AVXL

$11.26 +0.39 (+3.59%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$11.21 -0.05 (-0.44%)

As of 07/16/2025 07:47 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Esperion Therapeutics NASDAQ:ESPR

$1.12 -0.01 (-0.88%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$1.13 +0.01 (+0.89%)

As of 07/16/2025 07:59 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Arcus Biosciences NYSE:RCUS

$9.26 +0.23 (+2.56%)

Closing price 07/16/2025 03:59 PM Eastern

Extended Trading

$9.26 -0.01 (-0.06%)

As of 07/16/2025 06:16 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time